XUNFEIHEALTH (02506): The period of stable prices has ended, and the excess rights issue has become invalid.

XUNFEIHEALTH (02506) announced that the stabilizing price period for the global offering ended on January 22, 2025 (Wednesday), which is 30 days after the deadline for submitting the Hong Kong public offering application. The lead manager confirmed that there was no oversubscription of H shares in the international offering. The stabilizing manager (or any person acting on its behalf) did not take any stabilizing actions during the stabilizing price period. Therefore, the lead manager (on behalf of the international underwriters) did not exercise any oversubscription rights during the stabilizing price period, and these rights expired on January 22, 2025 (Wednesday). As a result, the company did not issue any H shares under the oversubscription rights. Following the end of the stabilizing price period, the public holding of shares amounted to approximately 15.67% of the total issued share capital of the company, which met the minimum public holding requirement for exemption.